Cargando…
Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study
PURPOSE: To explore the safety and role of tegafur/gimeracil/oteracil (S1) maintenance therapy (MT) in metastatic nasopharyngeal carcinoma (NPC) patients after response to first-line chemotherapy and to assess outcome-associated biomarkers. METHODS: This was a multicentre, open-label, randomized con...
Autores principales: | Lu, Ying, Huang, Haixin, Yang, Hui, Hu, Xiaohua, Liu, Meilian, Huang, Changjie, Feng, Xianbin, Chen, Xishan, Jiang, Zhou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349704/ https://www.ncbi.nlm.nih.gov/pubmed/36075994 http://dx.doi.org/10.1007/s00432-022-04341-2 |
Ejemplares similares
-
Gemcitabine Plus Platinum versus Docetaxel Plus Platinum as First-Line Therapy for Metastatic Nasopharyngeal Carcinoma: A Randomized Clinical Study
por: Yang, Hui, et al.
Publicado: (2021) -
Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study
por: Li, Wenhua, et al.
Publicado: (2016) -
Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma
por: Chia, Whay-Kuang, et al.
Publicado: (2014) -
Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
por: Pei, Zhengda, et al.
Publicado: (2023) -
Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study
por: Lu, Ying, et al.
Publicado: (2019)